Show simple item record

dc.contributor.authorLiu, Yinen_US
dc.contributor.authorFei, Tengen_US
dc.contributor.authorZheng, Xiaoqien_US
dc.contributor.authorBrown, Mylesen_US
dc.contributor.authorZhang, Pengen_US
dc.contributor.authorLiu, X. Shirleyen_US
dc.contributor.authorWang, Haiyunen_US
dc.date.accessioned2016-04-01T15:48:10Z
dc.date.issued2016en_US
dc.identifier.citationLiu, Yin, Teng Fei, Xiaoqi Zheng, Myles Brown, Peng Zhang, X. Shirley Liu, and Haiyun Wang. 2016. “An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine.” Scientific Reports 6 (1): 22120. doi:10.1038/srep22120. http://dx.doi.org/10.1038/srep22120.en
dc.identifier.issn2045-2322en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318656
dc.description.abstractAn individual tumor harbors multiple molecular alterations that promote cell proliferation and prevent apoptosis and differentiation. Drugs that target specific molecular alterations have been introduced into personalized cancer medicine, but their effects can be modulated by the activities of other genes or molecules. Previous studies aiming to identify multiple molecular alterations for combination therapies are limited by available data. Given the recent large scale of available pharmacogenomic data, it is possible to systematically identify multiple biomarkers that contribute jointly to drug sensitivity, and to identify combination therapies for personalized cancer medicine. In this study, we used pharmacogenomic profiling data provided from two independent cohorts in a systematic in silico investigation of perturbed genes cooperatively associated with drug sensitivity. Our study predicted many pairs of molecular biomarkers that may benefit from the use of combination therapies. One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer. This study demonstrates how pharmacogenomic data can be used to systematically identify potentially cooperative genes and provide novel insights to combination therapies in personalized cancer medicine.en
dc.language.isoen_USen
dc.publisherNature Publishing Groupen
dc.relation.isversionofdoi:10.1038/srep22120en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768263/pdf/en
dash.licenseLAAen_US
dc.titleAn Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicineen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalScientific Reportsen
dash.depositing.authorFei, Tengen_US
dc.date.available2016-04-01T15:48:10Z
dc.identifier.doi10.1038/srep22120*
dash.authorsorderedfalse
dash.contributor.affiliatedFei, Teng
dash.contributor.affiliatedBrown, Myles


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record